CPRX · Catalyst Pharmaceuticals, Inc.
$0.00
—
End-of-day data · updated 2026-07-25
Market cap
$4B
Enterprise value
$3B
Trailing P/E
18.2
Forward P/E
9.9
Dividend yield
—
Beta
0.74
Avg volume
3M
Employees
0K
2D change
—
5D change
—
10D change
—
30D change
—
60D change
—
MTD change
—
YTD change
—
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Technical data is temporarily unavailable for CPRX.
Analyst sentiment over time — CPRX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-28
Latest call per bank · past 12 months
Citigroup
Neutral$31.50
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-28 | HC Wainwright & Co. | Downgrade | Buy → Neutral | $35.00 → $31.50 |
| 2026-05-08 | Citigroup | Downgrade | Buy → Neutral | $35.00 → $31.50 |
| 2026-05-07 | Stephens & Co. | Downgrade | Overweight → Equal-Weight | $0.00 |
| 2026-03-03 | Citigroup | Maintains | Buy | $33.00 → $35.00 |
| 2025-11-07 | Citigroup | Maintains | Buy | $31.00 → $33.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
CPRX Price Chart
Loading chart for CPRX…
Fundamentals
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.